Sorafenib Terminated Phase 1 / 2 Trials for Hepatocellular Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT01348503Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
NCT00828594Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
NCT02323906Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer